NEWSROOM
Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.
In the headlines
Jeito Capital announces acquisition of portfolio company HI-Bio™ by Biogen Inc. (Nasdaq: BIIB) for up to $1.8 billion; Biogen to strengthen portfolio to help patients with severe immune-mediated disease
Biogen Inc. (Nasdaq: BIIB) to acquire HI-Bio™ for a total consideration of up to $1.8 billion which illustrates that HI-Bio™, with Jeito's ongoing strategic and operational support, has achieved significant progress in its late-stage clinical programs. This major exit...
Find all our press releases
Jeito Capital leads a $105 million Series C financing in Alentis Therapeutics to advance transformational medicines for Claudin-1 in cancer & fibrosis
Funds will support the Phase I/II clinical development of Alentis’ two first-in-class...
Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders
Noema Pharma's clinical-stage assets and diversified pipeline hold significant potential in...
Jeito Capital strengthens its support in Pulmocide with participation in $52 million financing
The Series C extension round will accelerate clinical development, manufacturing scale-up and...
Jeito Capital demonstrates European biopharma leadership with first exit with AstraZeneca acquisition of Neogene Therapeutics
Deal validates Jeito’s unique investment model of selecting high-quality assets developed by...
Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer
Jeito Capital co-leads oversubscribed EUR 50 million Series C financing with Brandon Capital...
Jeito Capital becomes significant investor in HI-Bio, a clinical-stage biotech company developing targeted therapies for patients with severe immune-mediated diseases
Jeito Capital participates in $120 million financing alongside ARCH Venture Partners and Monograph...
Face to face
Meet Jeito
9-11
September
All day long
IPEM Paris 2024
Jeito will be present at IPEM, the International Private Equity Market, an international forum bringing together the major players in Private Equity, in Paris, France.
25-26
September
All day long
Invest Europe – Venture Capital Forum 2024
Jeito will be present at the Venture Capital Forum 2024 of Invest Europe, a leading European conference for LPs and GPs engaged in VC activity, in Amsterdam, Netherlands. Dr Rafaèle Tordjman, Founder & CEO of Jeito Capital, will be sharing her views as a speaker on the conference “Maximising Exit Strategies” on the 26th of September from 4pm to 4.45pm.